<SEC-DOCUMENT>0001104659-21-011617.txt : 20210203
<SEC-HEADER>0001104659-21-011617.hdr.sgml : 20210203
<ACCEPTANCE-DATETIME>20210203170707
ACCESSION NUMBER:		0001104659-21-011617
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210203
DATE AS OF CHANGE:		20210203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-252280
		FILM NUMBER:		21587125

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>tm215233d1_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; font: bold 10pt Times New Roman, Times, Serif">PROSPECTUS</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 33%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: right">Filed Pursuant to Rule&nbsp;424(b)(3)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">Registration No.&nbsp;333-252280</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U><IMG SRC="tm215233d1_424b3img001.jpg" ALT="" STYLE="height: 55px; width: 343px"></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>APPLIED
DNA SCIENCES,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>259,000
SHARES OF COMMON STOCK ISSUED PURSUANT TO THE EXERCISE OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus relates to the resale by
the selling stockholders named herein, including their transferees, pledgees or donees, or their respective successors, of up to
259,000 shares (the &ldquo;Shares&rdquo;) of Applied DNA Sciences,&nbsp;Inc. (the &ldquo;Company&rdquo;)&rsquo;s common stock,
$.001 par value, issuable upon the exercise of warrants (the &ldquo;Warrants&rdquo;) to purchase 259,000 shares of common stock.
Dillon Hill Capital, LLC and its affiliate, Dillon Hill Investment Company LLC, are collectively, the &ldquo;Selling Stockholders.&rdquo;
For information about the Selling Stockholders, see &ldquo;Selling Stockholders&rdquo; on page&nbsp;20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock offered by the Selling
Stockholders will be issued pursuant to the exercise of Warrants in accordance with their terms. The Warrants were issued in connection
with certain Warrant Exercise Agreements entered into by us with each of the Selling Stockholders. See &ldquo;Private Placement
of Warrants.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not selling any securities under
this prospectus and will not receive any of the proceeds from the sale of common stock by the Selling Stockholders, except for
funds received from the exercise of Warrants held by the Selling Stockholders, if and when exercised for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders may sell shares
of common stock (the &ldquo;Securities&rdquo;) from time to time in the principal markets on which the common stock is quoted at
the prevailing market price, at prices related to prevailing market prices or in negotiated transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders may sell shares
to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions
from the Selling Stockholders, the purchasers of the shares, or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are registering the offer and sale of
the Securities pursuant to certain registration rights granted to the Selling Stockholders. The timing and amount of any sale of
common stock is within the sole discretion of each Selling Stockholder. We do not know when or in what amount the Selling Stockholders
may offer the Securities for sale. We will pay the expenses of registering these Securities, including legal and accounting fees.
All selling and other expenses incurred by the Selling Stockholders will be borne by the Selling Stockholders. See &ldquo;Plan
of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is traded on The Nasdaq
Capital Market under the symbol &ldquo;APDN.&rdquo; On February&nbsp;2, 2021, the closing sales price for our common stock on The
Nasdaq Capital Market was $11.10 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>The purchase of the common stock offered
through this prospectus involves a high degree of risk. You should consider carefully the risk factors beginning on page&nbsp;13
of this prospectus before purchasing any of the securities offered by this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>We may amend or supplement this prospectus
from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or
supplements carefully before you make your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
(&ldquo;SEC&rdquo;) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is February&nbsp;3,
2021.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><U>Page</U></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_001"><FONT STYLE="font-size: 10pt">ABOUT
    THIS PROSPECTUS</FONT></A></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_001"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_002"><FONT STYLE="font-size: 10pt">SPECIAL
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_002"><FONT STYLE="font-size: 10pt">2</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_003"><FONT STYLE="font-size: 10pt">PROSPECTUS
    SUMMARY</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_003"><FONT STYLE="font-size: 10pt">4</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_004"><FONT STYLE="font-size: 10pt">SUMMARY
    OF RISKS</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_004"><FONT STYLE="font-size: 10pt">9</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_005"><FONT STYLE="font-size: 10pt">CORPORATE
    INFORMATION</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_005"><FONT STYLE="font-size: 10pt">11</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_006"><FONT STYLE="font-size: 10pt">THE
    OFFERING</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_006"><FONT STYLE="font-size: 10pt">12</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_007"><FONT STYLE="font-size: 10pt">RISK
    FACTORS</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_007"><FONT STYLE="font-size: 10pt">13</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_008"><FONT STYLE="font-size: 10pt">USE
    OF PROCEEDS</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_008"><FONT STYLE="font-size: 10pt">16</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_010"><FONT STYLE="font-size: 10pt">PRIVATE
    PLACEMENT OF WARRANTS</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_010"><FONT STYLE="font-size: 10pt">18</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_011"><FONT STYLE="font-size: 10pt">SELLING
    STOCKHOLDERS</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_011"><FONT STYLE="font-size: 10pt">20</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_012"><FONT STYLE="font-size: 10pt">PLAN
    OF DISTRIBUTION</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_012"><FONT STYLE="font-size: 10pt">22</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_013"><FONT STYLE="font-size: 10pt">LEGAL
    MATTERS</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_013"><FONT STYLE="font-size: 10pt">25</FONT></A></TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ss_014"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_014"><FONT STYLE="font-size: 10pt">25</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_015"><FONT STYLE="font-size: 10pt">WHERE
    YOU CAN FIND MORE INFORMATION</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_015"><FONT STYLE="font-size: 10pt">25</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#ss_016"><FONT STYLE="font-size: 10pt">INFORMATION
    INCORPORATED BY REFERENCE</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ss_016"><FONT STYLE="font-size: 10pt">25</FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should rely only on the information
provided in or incorporated by reference in this prospectus, in any prospectus supplement or in a related free writing prospectus,
or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not authorized any dealer, agent
or other person to give any information or to make any representation other than those contained or incorporated by reference in
this prospectus and any accompanying prospectus supplement or any related free writing prospectus. You must not rely upon any information
or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement or any
related free writing prospectus. This prospectus and any accompanying prospectus supplement and any related free writing prospectus,
if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities
to which they relate, nor do this prospectus and any accompanying prospectus supplement and any related free writing prospectus,
if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom
it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in
this prospectus and any accompanying prospectus supplement and any related free writing prospectus, if any, is accurate on any
date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is
correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying
prospectus supplement and any related free writing prospectus is delivered or securities are sold on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not done anything that would permit
this offering or possession or distribution of this prospectus or any free writing prospectus in any jurisdiction where action
for that purpose is required, other than in the United States. You are required to inform yourself about and to observe any restrictions
relating as to this offering and the distribution of this prospectus and any such free writing prospectus outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference
in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose
of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant
to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In this prospectus &ldquo;Applied DNA,&rdquo;
the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Applied DNA Sciences,&nbsp;Inc. and
its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_002"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus and any applicable prospectus
supplement or free writing prospectus and the documents incorporated by reference herein and therein contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), that are intended to
qualify for the &ldquo;safe harbor&rdquo; created by those sections. In addition, we may make forward-looking statements in other
documents filed with or furnished to the SEC, and our management and other representatives may make forward-looking statements
orally or in writing to analysts, investors, representatives of the media and others. These statements relate to future events
or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements
expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Forward-looking statements can generally
be identified by the fact that they do not relate strictly to historical or current facts and include, but are not limited to,
statements using terminology such as &ldquo;can&rdquo;, &ldquo;may&rdquo;, &ldquo;could&rdquo;, &ldquo;should&rdquo;, &ldquo;assume&rdquo;,
 &ldquo;forecasts&rdquo;, &ldquo;believe&rdquo;, &ldquo;designed to&rdquo;, &ldquo;will&rdquo;, &ldquo;expect&rdquo;, &ldquo;plan&rdquo;,
 &ldquo;anticipate&rdquo;, &ldquo;estimate&rdquo;, &ldquo;potential&rdquo;, &ldquo;position&rdquo;, &ldquo;predicts&rdquo;, &ldquo;strategy&rdquo;,
 &ldquo;guidance&rdquo;, &ldquo;intend&rdquo;, &ldquo;seek&rdquo;, &ldquo;budget&rdquo;, &ldquo;project&rdquo; or &ldquo;continue&rdquo;,
or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future,
including risks relating to the continuing outbreak of the coronavirus (COVID-19). You should read statements that contain these
words carefully because they:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>discuss our future expectations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>contain projections of our future results of operations or of our financial condition; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>state other &ldquo;forward-looking&rdquo; information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe it is important to communicate
our expectations. However, forward-looking statements are based on our current expectations, assumptions, estimates and projections
about our business and our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly, our
actual results and the timing of certain events may differ materially from those expressed or implied in such forward-looking statements
due to a variety of factors and risks, including, but not limited to, those set forth under &ldquo;Risk Factors&rdquo; and &ldquo;Prospectus
Summary &ndash; Our Company&rdquo; set forth in this prospectus and those set forth from time to time in our other filings with
the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our forward-looking statements address,
among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our expectations of future revenues, expenditures, capital or other funding requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the adequacy of our cash and working capital to fund present and planned operations and growth;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our business strategy and the timing of our expansion plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our expectations concerning product candidates for our technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our expectations concerning existing or potential development and license agreements for third-party collaborations and joint
ventures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our expectations of when different phases of clinical activity may commence and conclude;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the effect of governmental regulations generally;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our expectations of when regulatory submissions may be filed or when regulatory clearances or approvals may be received; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our expectations of when or if we will become profitable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any or all of our forward-looking statements
may turn out to be wrong. They may be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties.
Actual outcomes and results may differ materially from what is expressed or implied in our forward-looking statements. Among the
factors that could affect future results are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the inherent uncertainties of product development based on our new and as yet not fully proven technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the risks and uncertainties regarding the actual effect on humans of seemingly safe and efficacious formulations and treatments
when tested clinically;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the inherent uncertainties associated with clinical trials of product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the inherent uncertainties associated with the process of obtaining regulatory clearance or approval to market product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the inherent uncertainties associated with commercialization of products that have received regulatory clearance or approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>economic and industry conditions generally and in our specific markets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the volatility of, and decline in, our stock price; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our current lack of financing for operations and our ability to obtain the necessary financing to fund our operations and effect
our strategic development plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All forward-looking statements and risk
factors included in this prospectus and the documents incorporated herein by reference are made as of the date hereof, or in the
case of documents incorporated by reference, the original date of any such documents, based on information available to us as of
such date, and we assume no obligations to update any forward-looking statement or risk factor, unless we are required to do so
by law. If we do update one or more forward-looking statements, no inference should be drawn that we will make updates with respect
to other forward-looking statements or that we will make any further updates to those forward-looking statements at any future
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of the assumptions underlying the forward-looking
statements contained in this prospectus and the documents incorporated herein by reference could prove inaccurate and, therefore,
we cannot assure you that the results contemplated in any of such forward-looking statements will be realized. Based on the significant
uncertainties inherent in these forward-looking statements, the inclusion of any such statement should not be regarded as a representation
or as a guarantee by us that our objectives or plans will be achieved, and we caution you against relying on any of the forward-looking
statements contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_003"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This summary highlights certain information
about us, this offering and information appearing elsewhere in this prospectus and in the documents we incorporate by reference
in this prospectus. This summary is not complete and does not contain all of the information that you should consider before investing
in our securities. After you carefully read this summary, to fully understand our company and this offering and its consequences
to you, you should read this entire prospectus and any related free writing prospectus authorized by us, including the information
referred to under the heading &ldquo;Risk Factors&rdquo; in this prospectus beginning on page&nbsp;13, and any related free writing
prospectus, as well as the other documents that we incorporate by reference into this prospectus, including our financial statements
and the notes to those financial statements, which are incorporated herein by reference from our <A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465920136828/tm2037742d1_10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form&nbsp;10-K for the year ended September&nbsp;30, 2020, filed on December&nbsp;17, 2020</A>, as amended by <A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921008158/tm214175d1_10ka.htm" STYLE="-sec-extract: exhibit">Amendment No.&nbsp;1 filed on January&nbsp;27, 2021</A>. Please read &ldquo;Where You Can Find More Information&rdquo; on page&nbsp;25 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our proprietary PCR-based DNA LinearDNA<SUP>TM
</SUP>manufacturing platform produces large quantities of DNA for use in nucleic acid-based in vitro medical diagnostics and preclinical
nucleic acid-based drug development and manufacturing markets (&ldquo;Biotherapeutic Contract Research and Manufacturing&rdquo;)
and for supply chain security, anti-counterfeiting and anti-theft technology purposes (&ldquo;Non-Biologic Tagging&rdquo;). In
response to the SARS-CoV-2 (&ldquo;COVID-19&rdquo;) pandemic, the Company developed a PCR-based molecular diagnostic test for COVID-19,
which was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) in May&nbsp;2020.
The Company currently manufactures and sells its EUA authorized COVID-19 molecular diagnostic test kit under the Linea<SUP>TM </SUP>COVID-19
Assay Kit trademark (&ldquo;COVID-19 Diagnostic Testing&rdquo;). In addition, and in further response to the COVID-19 pandemic,
the Company developed and is currently offering non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19
in defined populations. The Company&rsquo;s COVID-19 pooled surveillance testing services are currently offered under the safeCircle<SUP>TM</SUP>
trademark (&ldquo;COVID-19 Surveillance Testing&rdquo;). The Company is also developing an invasive circulating tumor cell capture
and identification technology (&ldquo;iCTC Technology&rdquo;) which uses a patented functional assay to capture live invasive circulating
tumor cell and associated lymphocytes that can be identified and expanded for further analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Applied DNA&rsquo;s LinearDNA<SUP>TM</SUP>
PCR platform is capable of producing large scale DNA, which we believe offers many benefits over the limitations of other large
scale DNA manufacturing systems, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Speed &ndash; Production of DNA via the LinearDNA<SUP>TM</SUP> platform can be measured in terms of hours, not days and weeks
like other large scale DNA manufacturing platforms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Scale &ndash; The LinearDNA<SUP>TM</SUP> platform is flexible and can be adapted to encompass large quantity production.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Purity &ndash; DNA produced via PCR is pure, resulting in only large quantities of the target DNA sequence. Unwanted DNA sequences
such as bacterially-derived DNA are not present.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Customization &ndash; DNA produced via PCR can be easily chemically modified to suit specific customer applications.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Biotherapeutic Contract Research and Manufacturing</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our patented continuous flow PCR systems
and other proprietary PCR-based production technology and post-processing systems that comprise the LinearDNA<SUP>TM</SUP> platform
allows for the large-scale production of specific DNA sequences. The LinearDNA<SUP>TM</SUP> platform is currently being used for
customers to manufacture DNA as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development
in the fields of adoptive cell therapies (CART and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based therapies and gene therapies. We believe our LinearDNA<SUP>TM</SUP>
platform confers a distinct competitive advantage in cost, cleanliness, and time-to-market as compared to other DNA manufacturing
systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We provide preclinical contract research
and manufacturing services for the nucleic acid-based therapeutic markets. We work with biotech and pharmaceutical companies to
convert plasmid-based and/or viral transduction-based preclinical biotherapeutics into PCR-produced linear DNA-based forms that
can be produced on our LinearDNA<SUP>TM</SUP> platform. In addition, we provide contract research services to RNA based drug and
biologic customers for preclinical studies. These services include the design, development and manufacture of PCR-produced DNA
templates for RNA. In addition, we also use our LinearDNA<SUP>TM</SUP> platform to produce very large gram-scale quantities of
DNA for the in vitro diagnostic market where our DNA is used for both commercially available diagnostics and diagnostics under
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also seek to develop, acquire, and commercialize,
ourselves or with partners, a diverse portfolio of nucleic acid-based therapeutics based on PCR-produced linear DNA to improve
existing nucleic acid-based therapeutics or to create new nucleic acid-based therapeutics that address unmet medical needs. We
are currently directly engaged in preclinical drug candidate development activities focusing on therapeutically-relevant DNA constructs
manufactured via our LinearDNA<SUP>TM</SUP> platform in the fields of DNA-based anti-viral and anti-cancer vaccines, CAR-T cell
immunotherapy and the manufacture of rAAV vectors for gene therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are also engaged in preclinical and animal
drug candidate development activities focusing on therapeutically relevant DNA constructs manufactured via our PCR-based production
platform. We seek to develop, acquire and commercialize, alone or with partners, a diverse portfolio of nucleic acid-based therapeutics
based on PCR-produced linear DNA which we believe will improve existing nucleic acid-based therapeutics or create new nucleic acid-based
therapeutics that address unmet medical needs. To this end, we are currently working with our development partners Takis S.R.L.
and Evvivax S.R.L. (&ldquo;Takis/Evvivax&rdquo;) to develop an amplicon-based linear DNA vaccine for COVID-19 that would be manufactured
on our LinearDNA<SUP>TM</SUP> platform. Together with our development partners, our amplicon-based linear COVID-19 vaccine candidate
has shown efficacy in preclinical cell and small animal studies. In September&nbsp;2020, we entered into an Animal Clinical Trial
Agreement with Takis/Evvivax and with Veterinary Oncology Services, PLLC, an affiliate of Guardian Veterinary Specialists (&ldquo;GVS&rdquo;),
a multi-specialty veterinary hospital. In November&nbsp;2020, we, together with Takis/Evvivax and GVS, announced receipt of approvals
from the New York State Department of Agriculture and Markets and the U.S. Department of Agriculture (&ldquo;USDA&rdquo;) on an
advanced clinical strategy to conduct a veterinary trial of a vaccine candidate. Our jointly-developed amplicon-based DNA vaccine
for COVID-19 is expected to start veterinary clinical trials in domestic feline cats by early 2021, with the end goal of applying
for a USDA Animal and Plant Health Inspection Service conditional license to enable commercial veterinary sales for domestic felines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>COVID-19 Diagnostic Testing</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May&nbsp;13, 2020 we received an EUA
from the FDA for the clinical use of the Linea<SUP>TM</SUP> COVID-19 Assay Kit for the qualitative detection of nucleic acid from
SARS-CoV-2 in respiratory specimens including anterior nasal swabs, self-collected at a healthcare location or collected by a healthcare
worker, and nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates,
and bronchoalveolar lavage specimens collected by a healthcare worker from individuals who are suspected of COVID-19 by their healthcare
provider. Under the EUA, testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988,
42 U.S.C. &sect;263a (&ldquo;CLIA&rdquo;), that meet requirements to perform high complexity tests, which certification we have
applied for but have not yet obtained. As a result, we currently can sell the tests to CLIA laboratories that satisfy such requirements
to perform high complexity tests, but we cannot currently perform the test for the purpose of providing patient specific results.
Subsequently, during July&nbsp;and November&nbsp;2020, we were granted EUA amendments that expand the installed base of PCR equipment
platforms on which our Linea&trade; COVID-19 Assay Kit can be processed and significantly increased the daily testing capacity
of the Linea&trade; COVID-19 Assay Kit through the use of automation. The scope of the EUA, as amended, is expressly limited to
use consistent with the Instructions for Use by authorized laboratories, certified under CLIA to perform high complexity tests.
The EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in
vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated or until the EUA&rsquo;s prior termination or revocation.
Our Linea&trade; COVID-19 Assay Kit has not been FDA cleared or approved, and the EUA&rsquo;s limited authorization is only for
the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. We currently manufacture the Linea<SUP>TM</SUP>
COVID-19 Assay Kit at our facilities in Stony Brook, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September&nbsp;29, 2020 we announced
that we had entered into a Master Services Agreement with Stony Brook University Hospital to supply the Linea<SUP>TM</SUP> COVID-19
Assay Kit and related automation systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>COVID-19 Surveillance Testing</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Starting in July&nbsp;2020, the Company
under its wholly-owned subsidiary, Applied DNA Clinical Labs LLC (&ldquo;ADCL&rdquo;), began offering COVID-19 pooled surveillance
testing to customers as a Testing-as-a-Service (TaaS) offering branded under the safeCircle<SUP>TM</SUP> trademark. Unlike diagnostic
testing, which looks for the occurrence of COVID-19 at the individual level, safeCircle<SUP>TM</SUP> surveillance testing looks
for infections within a defined population or community and can be used for making health management decisions at the population
level. safeCircle<SUP>TM</SUP> surveillance testing uses high-sensitivity pooled COVID-19 testing utilizing the Linea&trade; COVID-19
Assay Kit. Under the safeCircle<SUP>TM</SUP> surveillance testing service, pooled test results are returned to the sponsoring organization
in the aggregate only, not directly to the participating individuals, and may be performed without CLIA certification. Once potentially
infected portions of a defined population are identified by the safeCircle<SUP>TM</SUP> surveillance testing service, the individuals
comprising the potentially infected portions of the defined population are referred to follow on diagnostic testing at a clinical
lab to obtain individual results. ADCL is offering its safeCircle<SUP>TM</SUP> surveillance testing in compliance with current
CDC, FDA, CMS and New York State Department of Health recommendations. The use of pooled sampling procedures for the safeCircle<SUP>TM</SUP>
surveillance testing service has been internally validated by ADCL in compliance with current CDC guidance. The use of pooled sampling
procedures is not included in the Linea<SUP>TM</SUP> COVID-19 Assay Kit EUA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We seek to commercialize the safeCircle<SUP>TM</SUP>
surveillance testing TaaS offering with institutional clients such as schools, colleges and businesses. We currently provide safeCircle<SUP>TM</SUP>
surveillance testing to several private schools, New York State-based small enterprises and college athletic programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Clinical Testing Laboratory</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our ADCL subsidiary, we have applied
to the New York State Department of Health for all necessary licensing to operate a New York State clinical diagnostics laboratory.
These applications are currently pending. Until this licensing is obtained, we will be unable to operate a clinical diagnostic
laboratory and cannot provide individual patient testing results. The New York State Department of Health performed its initial
inspection of our clinical laboratory and identified deficiencies in the clinical standard of practice. These deficiencies need
to be rectified before we can submit a request for re-inspection. We are working to rectify these deficiencies now. Through ADCL,
we seek to further commercialize our EUA authorized Linea<SUP>TM</SUP> COVID-19 Assay Kit and our iCTC Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>iCTC Technology</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We seek to further develop, manufacture
and commercialize our Vita-Assay<SUP>TM</SUP> iCTC Technology acquired from Vitatex,&nbsp;Inc. in August&nbsp;2019. Our iCTC Technology
uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes that can be identified
and expanded for further analysis, including genetic sequencing. We believe our iCTC Technology can be used as an early cancer
diagnostic tool, to facilitate cancer disease progression monitoring, to assess metastatic tumor risk and to discover epitopes
to serve as targets for nucleic-acid based immunotherapies. Our iCTC Technology has been used and is currently being used in a
human cancer drug candidate clinical trial to monitor cancer disease progression in the trial subjects as a Research Use Only diagnostic
assay. We believe our iCTC Technology has several advantages over existing in vitro circulating tumor cell diagnostic technologies
that do not capture live iCTC cells. The Company seeks to further develop and commercialize this technology and to potentially
integrate aspects of the iCTC Technology with the LinearDNA<SUP>TM</SUP> platform for cancer research and nucleic-acid based drug
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Non-Biologic Tagging and Security Products and Services</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our supply chain security business allows
our customers to use non-biologic DNA (molecular) tags manufactured on our LinearDNA<SUP>TM</SUP> platform to mark objects in a
unique manner and then identify these objects by detecting the absence or presence of the molecular tag. We believe our molecular
tags are not economically feasible nor practical to replicate, and that our disruptive tracking platform offers broad commercial
relevance across many industry verticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underlying strategy in our tagging business
is to become an authenticity and traceability platform provider for large complex supply chains, particularly in process industries
in which contracts for our products and services are typically larger and recurring over longer duration as compared to our historic
norms, where the benefits to customers and consumers are more significant, and where our forensic security and traceability offer
a unique and protected value. Using our tagging products and technology, manufacturers, brands, and other stakeholders can ensure
authenticity and protect against diversion throughout a product&rsquo;s journey from manufacturer to use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SigNature&reg; Molecular Tags, SigNature&reg;
T Molecular Tags, fiberTyping&reg;, SigNify&reg; Beacon&reg; and CertainT&reg; comprise our principal Non-Biologic tagging and
security technology platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Signature Molecular Tags</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SigNature&reg; molecular tags manufactured
via our LinearDNA<SUP>TM</SUP> platform form the core of our supply chain security technology platform. They provide forensic power
and protection for a wide array of applications. Highly secure, robust and durable, SigNature&reg; molecular tags are an ingredient
that can be used to fortify brand protection efforts; strengthen supply chain security; and mark, track and convict criminals.
Through our SigNature&reg; molecular tags, custom DNA sequences can be embedded into a wide range of host carriers including natural
and synthetic materials such as cotton, leather, cannabis, ink, varnish, thread, metal coatings, and pharmaceuticals and nutraceuticals.
SigNature&reg; molecular tag formulations are made to be resistant to challenging environments such as heat, cold, vibration, abrasion,
organic solvents, chemicals, UV radiation and other extreme environmental conditions, and can be identified for numerous years
after being embedded directly into or on an item. The sequence of each individual molecular tag is recorded and stored in a secure
database so that we can later detect it to obtain definitive proof of the presence or absence of a specific molecular tag using
a simple in-field test, or in our laboratories. Our in-lab forensic testing capability delivers Certificate of DNA Authentication
(&ldquo;CODA&rdquo;) or an expert witness report, with expert witness services for some cases. Because DNA can be amplified with
high fidelity, only minute quantities of our molecular tags extracted from our customers&rsquo; goods are necessary for successful
analysis and authentication. As a result, SigNature&reg; molecular tags can fold seamlessly into production and logistics workflows
at extremely low concentrations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our SigNature&reg; molecular tags can be
uniquely designed for specific industries. For example, our SigNature&reg; T molecular tags, designed for textiles and apparel
industry, are specially engineered to adhere tenaciously to textile substrates, which make them resistant to standard textile production
conditions. The result is an enduring forensic level molecular tag that remains present from the fiber stage through to the finished
product. Overall SigNature&reg; molecular tags now exist on hundreds of millions of commodity goods ranging from consumer product
packaging to microcircuits to cotton and synthetic fibers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>SigNify&reg;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SigNify&reg; IF portable DNA readers and
SigNify&reg; consumable reagent test kits provide definitive real-time authentication of molecular tags in the field, providing
a front-line solution for supply chain integrity backed with forensic-level molecular tag authentication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CertainT<SUP>&reg;</SUP></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The CertainT&reg; trademark indicates the
use of our tagging, testing and tracking platforms and solutions, enabling manufacturers, brands and trade organizations to convey
proof of their product claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CertainT&reg; and other customer applications
include the use of a software platform that enables customers to manage the security of company-marked goods from point of marking
to point of authentication or validation to end of life. The base platform is configurable to customer requirements. Basic functions
offered include molecular tag inventory management, program training and communications, a database of marked items information,
associated documents and images, chain of custody and location tracking, sample authentication processing and CODA downloads, and
other administrative functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>FDA Alert and Letter Regarding the Linea&trade; COVID-19
Assay Kit and COVID-19 Mutations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December&nbsp;29, 2020 the Company received
a letter (the &ldquo;FDA Information Request&rdquo;)&nbsp; from the FDA requesting certain information about the potential impact
of the 69-70del SARS-CoV-2 (&ldquo;COVID-19&rdquo;) mutation (the &ldquo;69-70del mutation&rdquo;) on the performance of the Linea&trade;
COVID-19 Assay Kit. The 69-70del mutation is a mutation in the S-gene of COVID-19 that is found in several variants of COVID-19,
including, but not limited to the so called &ldquo;UK Variant,&rdquo; whose technical designation is UK COV202012/01 or the B.1.1.7
variant.&nbsp; The B.1.1.7 variant contains many mutations, including the 69-70del mutation.<FONT STYLE="color: #333333">&nbsp;
</FONT>The B.1.1.7 variant has been associated with an increased risk of transmission.&nbsp; As a result, early identification
of individuals potentially infected with this variant is important because it could reduce further transmission of COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In response to the FDA Information Request,
the Company performed analysis of the Linea&trade; COVID-19 Assay Kit&rsquo;s performance in the presence of the 69-70del mutation.
Results showed that sensitivity of one of the Linea&trade; COVID-19 Assay Kit&rsquo;s two targets, specifically the S1 target,
was highly diminished in the presence of the 69-70del mutation. The sensitivity of the Linea&trade; COVID-19 Assay Kit&rsquo;s
other target (S2) was not impacted by the mutation. This results in a detection pattern in the presence of the 69-70del mutation
where the sensitivity of the Linea&trade; COVID-19 Assay Kit&rsquo;s S1 target is highly reduced as compared to the sensitivity
of the Linea&trade; COVID-19 Assay Kit&rsquo;s S2 target (&ldquo;S-gene target dropout&rdquo;). While reduced sensitivity with
molecular diagnostics is typically not desirable, with certain multi-target COVID-19 molecular diagnostic tests such as the Linea&trade;
COVID-19 Assay Kit, reduced sensitivity in regard to one target allows viral variants to be identified while still detecting the
presence of COVID-19 via the assay&rsquo;s other target(s). On December&nbsp;31, 2020, the Company responded to the FDA Information
Request informing the FDA of the Linea&trade; COVID-19 Assay Kit&rsquo;s S-gene target dropout in the presence of the 69-70del
mutation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January&nbsp;8, 2021, the FDA issued
an Alert to Health Care Providers and Clinical Laboratory Staff (the &ldquo;FDA Alert&rdquo;) regarding the potential impact of
COVID-19 mutations on the accuracy of COVID-19 molecular diagnostic tests. Coincident with the FDA Alert, the FDA also issued a
Letter to Health Care Providers and Clinical Laboratory Staff (the &ldquo;FDA Letter&rdquo;). The FDA Alert and the FDA Letter
advised that false negatives are a risk with all laboratory tests, including COVID-19 molecular diagnostic tests. The FDA further
advised that false negatives can occur with any COVID-19 molecular diagnostic test if a mutation occurs in the region of the virus
that the test is designed to assess. The FDA explained that the potential for false negatives with COVID-19 molecular diagnostics
may be increased with tests that only assess a single region of the COVID-19 virus as compared to tests that assess more than one
region of the virus. The FDA stated that it believes the overall impact of COVID-19 mutations on testing accuracy will be low.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA Alert and the FDA Letter also stated
that FDA is conducting continuous data analysis to evaluate all currently EUA authorized molecular tests in light of COVID-19 mutations.
Based on the FDA&rsquo;s own analysis and input from manufacturers, the FDA Alert and the FDA Letter identified three EUA authorized
molecular diagnostic tests that might be impacted by currently known COVID-19 mutations. The FDA Alert and the FDA Letter stated
that the Linea&trade; COVID-19 Assay Kit and one other molecular diagnostic test exhibit S-gene target dropout detection patterns
when certain COVID-19 variants are present, including variants with the 69&mdash;70del mutation, which includes the B.1.1.7 variant.&nbsp;
The FDA Letter further stated that this detection pattern may help with the early identification of new COVID-19 variants in patients,
including variants with the 69&mdash;70del mutation, which could help to reduce the further spread of COVID-19. The FDA Letter
further noted that when the S-gene target dropout is observed in patient samples tested with the identified kits such samples should
be considered for further characterization via full genetic sequencing, which would allow for identification of the specific variant
at issue. The FDA letter further concluded that due to the identified kits&rsquo; multi-target design, overall test sensitivity
should not be impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Preliminary First Quarter 2021 Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January&nbsp;4, 2021, the Company announced
that it expects revenues for the first fiscal quarter of 2021 ended December&nbsp;31, 2020, to be in the range of $1.3 million
to $1.6 million compared to revenues of $314,000 in the fourth quarter of fiscal 2020. The sequential growth in quarterly revenues
is driven principally by demand for safeCircle&trade;, the pooled COVID-19 surveillance testing program offered by the Company&rsquo;s
subsidiary, ADCL, and from sales of its Linea&trade; COVID-19 Assay Kit under EUA by the FDA EUA). These preliminary unaudited
results are based on management&rsquo;s initial analysis of operations for the first fiscal quarter of 2021 ended December&nbsp;31,
2020, and are subject to review and revision. The Company expects to issue full financial results for the first fiscal quarter
of 2021 in mid-February.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_004"></A>SUMMARY
OF RISKS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business is subject to numerous risks
and uncertainties, discussed in more detail in the section &ldquo;Risk Factors.&rdquo; These risks include, among others, the following
key risks:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>The COVID-19 global pandemic may continue to materially and adversely impact our business, financial condition and results
of operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Our ability to continue as a going concern.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>We have a history of net losses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>We have not produced significant revenues. This makes it difficult to evaluate our future prospects and increases the risk
that we will not be successful.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Our opportunities in medical devices, pharmaceuticals and biologics will require substantial additional funding. We may not
be successful in our efforts to create a pipeline of product candidates or to develop commercially successful products. If we fail
to successfully identify, finance and develop product candidates, our commercial opportunities in medical devices, pharmaceuticals
and biologics may be limited.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Our Linea<SUP>TM</SUP> COVID-19 Assay Kit is being sold under a FDA EUA which could be revoked or terminated by the FDA at
any time and will cease to be effective once the public health emergency justifying its use ends.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Our COVID-19 Surveillance Testing may become obsolete for a variety of reasons, including an end to the current pandemic. The
utility will also be diminished if positivity rates reach levels high enough to render surveillance testing ineffective or inefficient.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Our Linea<SUP>TM</SUP> COVID-19 Assay Kits could become obsolete or their utility could be significantly diminished.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Medical device, pharmaceutical and biologic products are highly complex, and if we or our collaborators and customers are unable
to provide quality and timely offerings to our respective customers, our business could suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Pharmaceutical and biologic-related revenue will be dependent on our collaborators&rsquo; and customers&rsquo; demand for our
manufacturing services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>The markets for our medical devices, drug and biologic candidates and linear DNA are very competitive, and we may be unable
to continue to compete effectively in these industries in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>The markets for our supply chain security and product authentication solutions are very competitive, and we may be unable to
continue to compete effectively in these industries in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Intellectual property litigation could harm our business, financial condition and results of operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Our joint pursuit of a potential vaccine for COVID-19 is at an early stage and may be unable to produce a vaccine that successfully
treats the virus in a timely manner, if at all, and compete successfully with vaccines developed by larger companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Medical device, pharmaceutical and biologic-related revenue is generally dependent on regulatory authorization, clearance or
approval, oversight and compliance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>The regulatory authorization, clearance and approval processes of the FDA and comparable foreign regulatory authorities are
lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory authorization, clearance
or approval for our product candidates, we will be unable to generate product revenue from the related product candidates and our
business may be substantially harmed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>If the FDA were to begin to enforce regulation of Laboratory Developed Tests, we could incur substantial costs and delays associated
with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements if clearance
or approval is ever obtained.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>If we are unable to obtain laboratory licensure or we fail to comply with laboratory licensing requirements, we would not be
able to offer clinical diagnostic testing services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions
could be adversely affected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>We need to expand our sales, marketing and support organizations to increase market acceptance of our products and services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>If we are unable to continue to retain the services of Dr.&nbsp;Hayward, we may not be able to continue our operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>We may have conflicts of interest with our affiliates and related parties, and in the past we have engaged in transactions
and entered into agreements with affiliates that were not negotiated at arms&rsquo; length.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the above key factors, as
well as other variables affecting our operating results and financial condition, past financial performance may not be a reliable
indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. The
statements above and the statements included in &ldquo;Risk Factors&rdquo; are important factors that could cause actual results
or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and
uncertainties described above and in &ldquo;Risk Factors&rdquo; are not the only ones we face. In addition to the factors discussed
elsewhere in this prospectus and our other reports and documents filed with the SEC, risks and uncertainties not presently known
to us or that we may currently deem immaterial also may impair our business, financial condition, operating results and/or stock
price. If any of the risks and uncertainties described above or in &ldquo;Risk Factors&rdquo; actually occurs, our business, financial
condition, operating results and/or stock price could be harmed. In the foregoing factors and in &ldquo;Risk Factors&rdquo;, &ldquo;volatility
in our share price&rdquo;, &ldquo;adverse impact on the price (or value) of our shares&rdquo;, &ldquo;decline in the price of our
common stock&rdquo; and similar terms also refer to our warrants and shares to be received upon exercise of our warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_005"></A>CORPORATE
INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a Delaware corporation, which was
initially formed in 1983 under the laws of the State of Florida as Datalink Systems,&nbsp;Inc. In 1998, we reincorporated in the
State of Nevada, and in 2002, we changed our name to our current name, Applied DNA Sciences,&nbsp;Inc. In December&nbsp;2008, we
reincorporated from Nevada to the State of Delaware. LineaRx,&nbsp;Inc. was incorporated in Delaware on September&nbsp;11, 2018.
ADCL was formed in Delaware on June&nbsp;12, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our corporate headquarters are located at
the Long Island High Technology Incubator at Stony Brook University in Stony Brook, New York, where we established laboratories
for the manufacture of molecular tags, product prototyping, molecular tag authentication, bulk DNA production, as well the manufacture
of our Linea&trade; COVID-19 Assay Kit and the performance of our COVID-19 Surveillance Testing. The address of our corporate headquarters
is 50 Health Sciences Drive, Stony Brook, New York 11790, and our telephone number is (631) 240-8800. We maintain a website at
www.adnas.com where general information about us is available. The information on, or that may be accessed through, our website
is not incorporated by reference into and should not be considered a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1pt solid; padding-right: 5pt; padding-left: 5pt; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_006"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock to be offered:</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">259,000<SUP>(1)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms of the Offering:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Selling Stockholder will determine when and how to sell the Shares offered in this prospectus, as described in &ldquo;Plan of Distribution.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of proceeds:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not receive any proceeds from the sale of Shares in this offering.&nbsp;&nbsp;See the sections titled &ldquo;Use of Proceeds&rdquo; and &ldquo;Selling Stockholders&rdquo; for additional information.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should read the section titled &ldquo;Risk Factors&rdquo; for a discussion of factors to consider carefully, together with all the other information included in this prospectus, before deciding to invest in our common stock.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Capital Market symbol:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;APDN&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;Represents shares of common stock issuable upon exercise
of Warrants held by the Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders named in this prospectus may offer
and sell up to 259,000 shares of our common stock. Our common stock is currently listed on The Nasdaq Capital Market under the
symbol &ldquo;APDN.&rdquo; Shares of our common stock that may be offered under this prospectus will be fully paid and non-assessable.
We will not receive any of the proceeds of sales by the selling stockholders of any of the common stock covered by this prospectus.
We will, however, receive the net proceeds from any warrants that are exercised for cash. Throughout this prospectus, when we refer
to the shares of our common stock being registered on behalf of the selling stockholders for offer and resale, we are referring
to the shares of common stock that have been issued to the selling stockholders and the shares of common stock issuable upon exercise
of Warrants issued in the Private Placement described in the section titled &ldquo;Private Placement.&rdquo; When we refer to the
Selling Stockholders in this prospectus, we are referring to the Selling Stockholders identified in this prospectus and, as applicable,
their permitted transferees or other successors-in-interest that may be identified in a supplement to this prospectus or, if required,
a post-effective amendment to the registration statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></div>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_007"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Investment in our securities involves a
high degree of risk. In addition to the risks and investment considerations discussed elsewhere in this prospectus or any document
incorporated by reference herein, the following factors should be carefully considered by anyone purchasing the securities offered
by this prospectus. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial also may impair our business operations. We also update risk factors
from time to time in our periodic reports on Forms 10-K, 10-Q and 8-K which will be incorporated by reference in this prospectus.
If any of the following risks actually occur, our business could be harmed. In such case, the trading price of our common stock
could decline and investors could lose all or a part of their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See also the statements contained under
the heading &ldquo;Special Note Regarding Forward Looking Statements&rdquo; and &ldquo;Summary of Risks.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to this Offering:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If you purchase the common stock, you may experience immediate
dilution as a result of this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since the price per share of our common
stock being offered may be substantially higher than the net tangible book value per share of our common stock, you may suffer
immediate and substantial dilution in the net tangible book value of the common stock you purchase in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>You may experience future dilution as a result of future
equity offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to raise additional capital, we
may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common
stock that could result in further dilution to investors purchasing our common stock in this offering or result in downward pressure
on the price of our common stock. We may sell shares of our common stock or other securities in any other offering at prices that
are higher or lower than the prices paid by investors in this offering, and investors purchasing shares or other securities in
the future could have rights superior to existing stockholders. Moreover, to the extent that we issue options or warrants to purchase,
or securities convertible into or exchangeable for, shares of our common stock in the future and those options, warrants or other
securities are exercised, converted or exchanged, stockholders may experience further dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The trading price of our common stock has been, and is
likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which
are beyond our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our stock price is volatile. During the
period from January&nbsp;1, 2020 to January&nbsp;11, 2021, the closing price of our common stock ranged from a high of $15.21 per
share to a low of $2.80 per share. The stock market in general and the market for smaller pharmaceutical and biotechnology companies
in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies.
On January&nbsp;13, 2021, we closed a registered direct public offering of 1,810,000 shares of our common stock to certain institutional
investors, which may increase the volatility of our common stock. As a result of this volatility, you may not be able to sell your
common stock at or above the public offering price and you may lose some or all of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Business:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The COVID-19 global pandemic may continue to materially
and adversely impact our business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business has been and could continue
to be materially and adversely affected by the outbreak of a widespread health epidemic. The present coronavirus (or COVID-19)
pandemic has disrupted our operations and has affected our business, as government authorities impose mandatory closures, work-from-home
orders and social distancing protocols or impose other restrictions that could materially adversely affect our ability to adequately
staff and maintain our operations. Portions of our business are considered &ldquo;essential&rdquo; such as our government and pharmaceutical
contracts, as well as our vaccine and diagnostic candidate development and our COVID-19 Surveillance Testing. However, we have
experienced, and may continue to experience in the future, facility closures related to our &ldquo;nonessential&rdquo; businesses,
and pursuant to the government order, the Company has reduced the scope of its operations and where possible, certain workers are
telecommuting from their homes. As a result of COVID-19 we have experienced a decline in revenues from non-biological tagging and
related services. As the COVID-19 outbreak and responses to it continue to evolve, we may experience further adverse impacts on
our operations, including our ability to secure supplies, and our ability to access capital on favorable terms, or at all, may
be impaired. There may also be long-term effects on our customers in and the economies of affected countries. Although the duration
and ultimate impact of these factors is unknown at this time, the decline in economic conditions due to COVID-19, or another disease
causing similar impacts, may adversely affect our business, financial condition and results of operations and such impact may be
material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is substantial doubt relating to our ability to
continue as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have recurring net losses, which have
resulted in an accumulated deficit of $269,835,650 as of September&nbsp;30, 2020. We have incurred a net loss of $13,028,904 for
the fiscal year ended September&nbsp;30, 2020. At September&nbsp;30, 2020, we had cash and cash equivalents of $7,786,743. We have
concluded that these factors raise substantial doubt about our ability to continue as a going concern for one year from the issuance
of the financial statements. In addition, the report from our independent registered public accounting firm for the year ended
September&nbsp;30, 2020 includes an explanatory paragraph stating that our significant losses and needs to raise additional funds
to meet our obligations and sustain operations raise substantial doubt about our ability to continue as a going concern. On January&nbsp;13,
2021, we closed a registered direct public offering of 1,810,000 shares of our common stock to certain institutional investors
at a price of $8.30 per share resulting in total gross proceeds of approximately $15,000,000 before deducting placement agent fees
and other offering expenses. We will continue to seek to raise additional working capital through public equity, private equity
or debt financings. If we fail to raise additional working capital, or do so on commercially unfavorable terms, it would materially
and adversely affect our business, prospects, financial condition and results of operations, and we may be unable to continue as
a going concern. Future reports from our independent registered public accounting firm may also contain statements expressing substantial
doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the
future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources
may be unwilling to provide additional funding to us on commercially reasonable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our new emphasis on biotherapeutic contract research and
manufacturing and COVID-19 diagnostic and surveillance testing may reduce our ability to maintain and expand our existing Non-Biologic
Tagging businesses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our new emphasis on biotherapeutic contract
research and manufacturing and COVID-19 diagnostic and surveillance testing may divert funding and our limited managerial and other
resources from our existing non-biologic tagging businesses. This may have the effect of reducing opportunities to grow or maintain
revenues in our existing businesses while at the same time we may fail in our biotherapeutic contracts research and manufacturing
and COVID-19 diagnostic and surveillance testing efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Product Candidates, Manufacturing,
Development, and Industries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Linea<SUP>TM</SUP> COVID-19 Assay Kit is being sold
under an FDA EUA.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Linea<SUP>TM</SUP> COVID-19 Assay Kit
has not been cleared or approved by FDA, but has been authorized for sale under an EUA. The FDA has the authority to grant an EUA
to allow unapproved medical products to be used in an emergency when there are no adequate, approved, and available alternatives.
The EUA authorizes our test to be used by laboratories certified to perform high complexity testing under CLIA. The EUA includes
conditions of authorization with which we must comply, including, but not limited to, compliance with labeling, distribution of
materials designed to ensure proper use, reporting obligations, and restrictions on advertising and promotion. Distributors of
and laboratories using our Linea<SUP>TM</SUP> COVID-19 Assay Kit must also comply with the relevant provisions of our EUA. The
EUA is only effective for the duration of the COVID-19 public health emergency. The FDA may revoke or terminate the EUA sooner
if, for example, we fail to comply with the terms of the EUA or our test is determined to be less accurate than it was initially
believed to be. We cannot predict how long the EUA will remain in place. If the EUA is revoked or terminated, it could significantly
harm our business, results of operations, and profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our safeCircle<SUP>TM</SUP> surveillance testing service
could become obsolete or its utility could be significantly diminished.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Surveillance testing is not regulated by
the FDA and CMS has stated that CLIA certification is not required to conduct surveillance testing. ADCL is offering its safeCircle<SUP>TM</SUP>
surveillance testing in compliance with current CDC, FDA, CMS and New York State Department of Health recommendations. The regulatory
framework or recommendations regarding COVID-19 Surveillance Testing could change at any time. Further, our COVID-19 Surveillance
Testing may become obsolete for a variety of reasons, including an end to the current pandemic or the development and widespread
distribution of a vaccine, including the vaccines developed by Pfizer-BioNTech or Moderna for which the FDA has recently granted
emergency use authorization. In addition, the utility of these services will also diminish if positivity rates reach levels high
enough to render surveillance testing ineffective or inefficient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Linea<SUP>TM</SUP> COVID-19 Assay Kits could become
obsolete or their utility could be significantly diminished.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Linea<SUP>TM</SUP> COVID-19 Assay Kits
may become obsolete for a variety of reasons, including an end to the current pandemic, the development and widespread distribution
of a vaccine, including the vaccines developed by Pfizer-BioNTech or Moderna for which the FDA has recently granted emergency use
authorization. In addition, future or currently undiscovered mutations to the COVID-19 virus could result in our Linea<SUP>TM</SUP>
COVID-19 Assay Kits suffering a loss of sensitivity and resulting loss of utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit may result
in false negatives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">False negative test results are a risk with
all laboratory tests, including COVID-19 molecular diagnostic tests. A false negative occurs with a COVID-19 molecular diagnostic
when an individual who is infected with the virus tests negative for the virus.&nbsp; False negatives can occur in the presence
or absence of a mutation in the COVID-19 virus.&nbsp; In the presence of a mutation in the virus, false negatives can occur if
a mutation occurs in the region of the virus that the test is designed to assess.&nbsp; The risk of false negatives in the presence
of a mutation is increased with tests that only assess a single region of the COVID-19 virus as compared to tests that assess more
than one region of the virus.&nbsp; Our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit test assesses two regions of the virus, thus
reducing the likelihood of false negatives in the presence of one or more COVID-19 mutations.&nbsp; Regardless, false negatives
may occur with our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit in the presence or absence of one or more COVID-19 mutations.&nbsp;
If false negatives occur with our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit, individuals will incorrectly believe they do not
have COVID-19 and could further spread the virus thereby jeopardizing the health of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other companies may develop and obtain authorization for
molecular diagnostics that can detect the 69&mdash;70del mutation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 69&mdash;70del mutation is a mutation
that is found in several variants of COVID-19, including, but not limited to the so called &ldquo;UK Variant&rdquo; or the B.1.1.7
variant.&nbsp; The B.1.1.7 variant has been associated with an increased risk of transmission.&nbsp; According to an Alert to Health
Care Providers and Clinical Laboratory Staff and a Letter to Health Care Providers and Clinical Laboratory Staff both issued by
the FDA on January&nbsp;8, 2021, there are currently only two EUA authorized COVID-19 molecular diagnostics that can indicate a
sample contains the 69&mdash;70del mutation, including our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit.&nbsp; Other companies may
develop and obtain Emergency Use Authorization for COVID-19 molecular diagnostics that can detect the 69&mdash;70del mutation.&nbsp;
Such tests would compete with our test and could negatively impact sales of our Linea<SUP>TM&nbsp;</SUP>COVID-19 Assay Kit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_008"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will not receive any proceeds from the
sale of the shares of common stock by the Selling Stockholders. However, we will receive proceeds from the exercise of the Warrants
by the Selling Stockholders to the extent they are exercised for cash. We estimate that the maximum proceeds that we may receive
from the exercise of the Warrants, assuming all the Warrants are exercised at their average exercise price of $7.14, will be $1,850,360.
We do not know, however, whether any of the Warrants will be exercised or, if any of the Warrants are exercised, when they will
be exercised. It is possible that the Warrants will expire and never be exercised. There are circumstances under which the Warrants
may be exercised on a cashless basis. In these circumstances, even if the Warrants are exercised, we may not receive any proceeds,
or the proceeds that we do receive may be significantly less than what we might expect. We intend to use the aggregate net proceeds
from the exercise of the Warrants for general corporate purposes, including working capital, for research and development and to
advance the adoption of our LinearDNA&trade; manufacturing platform. The actual allocation of proceeds realized from the exercise
of these Warrants will depend upon the amount and timing of such exercises, our operating revenues and cash position at such time
and our working capital requirements. The Selling Stockholders will pay any expenses incurred by the Selling Stockholders for brokerage,
accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of their shares of common
stock. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus,
including, without limitation, all registration fees and fees and expenses of our counsel and our accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_009"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have never paid cash dividends on our
common stock. We anticipate that we will retain all of our future earnings, if any, for use in the expansion and operation of our
business and do not anticipate paying cash dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_010"></A>PRIVATE
PLACEMENT OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July&nbsp;17, 2019, we issued $1.5 million
of secured convertible notes (the &ldquo;July&nbsp;2019 Notes&rdquo;), bearing interest at a rate of 6% per annum, in a non-brokered
private placement with an accredited investor, Dillon Hill Capital, LLC, one of the Selling Stockholders hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November&nbsp;15, 2019, we closed an
underwritten public offering where we issued and sold 2,285,000 shares of our common stock and 2,285,000 accompanying common warrants
(the &ldquo;2019 Warrants&rdquo;) each with the right to purchase one share of our common stock at an exercise price of $5.25 per
share. In such offering, the Selling Stockholders purchased certain of the 2019 Warrants. On October&nbsp;7, 2020, we entered into
Warrant Exercise Agreements (each, a &ldquo;Warrant Exercise Agreement&rdquo;) with each of the Selling Stockholders, whereby 318,000
of our 2019 Warrants were exercised. The gross proceeds to the Company from this partial exercise of the 2019 Warrants was $1,669,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October&nbsp;9, 2020, the Company entered
into a letter agreement with Dillon Hill Capital, LLC as sole holder of the July&nbsp;2019 Notes for the repayment in full of such
notes, in an aggregate amount of $1,665,581, representing their outstanding principal amount plus accrued but unpaid interest through
their scheduled maturity date. The Company paid such payoff amount on October&nbsp;9, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In consideration of this partial exercise
of the 2019 Warrants and of the consent to repayment of the July&nbsp;2019 Notes, the Company agreed to issue pursuant to the Warrant
Exercise Agreement (the &ldquo;Private Placement&rdquo;), in addition to the 318,000 shares of common stock issued upon exercise
of the 2019 Warrants, 159,000 replacement warrants (the &ldquo;Warrants&rdquo;) to the Selling Stockholders, which is an amount
equal to one-half the amount of the 2019 Warrants exercised pursuant to the Warrant Exercise Agreements. The Warrants have an average
exercise price of $7.54, the closing price on The Nasdaq Capital Market of the Company&rsquo;s common stock on the date of the
applicable warrant exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The quantity, issue date, exercise price
and expiration date of the Warrants are listed in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Quantity</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Issuance Date</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Exercise Price</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Expiration Date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: right">159,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24%; font: 10pt Times New Roman, Times, Serif">October&nbsp;7, 2020</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 22%; font: 10pt Times New Roman, Times, Serif; text-align: right">7.54</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24%; font: 10pt Times New Roman, Times, Serif">October&nbsp;7, 2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">December&nbsp;9, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.57</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">December&nbsp;9, 2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">December&nbsp;10, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.46</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">December&nbsp;10, 2025</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each Warrant is exercisable for one share
of common stock beginning on the date of issuance thereof and ending on the five year anniversary of such date. The exercise price
and number of shares of common stock issuable upon exercise of the Warrants are subject to adjustment in the event of any stock
dividend, split, recapitalization, reorganization or similar transaction, as described in the Warrants. Subject to limited exceptions,
a holder of a Warrant will not have the right to exercise any portion of its Warrant if the holder, together with its affiliates,
would beneficially own in excess of 9.99% of the number of shares of common stock outstanding immediately after giving effect to
such exercise (the &ldquo;Beneficial Ownership Limitation&rdquo;); provided that upon 61 days&rsquo; prior notice to the Company,
the holder may elect to increase or decrease the Beneficial Ownership Limitation, although in no event may the Beneficial Ownership
Limitation exceed 9.99%. Each Warrant includes an adjustment provision that, subject to certain exceptions, reduces its exercise
price if the Company issues common stock or common stock equivalents at a price lower than the then-current exercise price of such
Warrant, subject to a minimum exercise price of 21% of such Warrant&rsquo;s initial exercise price per share. Under certain limited
circumstances, including that the daily volume weighted average price of the common stock for each of 20 consecutive trading days
has exceeded three times the exercise price of such Warrant, the Company may call for cancellation of all or any portion of such
Warrant for which a notice of exercise has not yet been delivered for consideration equal to $0.001 per share of common stock for
which such Warrant is excisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Warrants will not be registered nor
listed on any exchange but are the subject of registration rights agreements, entered into with each Selling Stockholder concurrently
with the respective Warrant Exercise Agreement, pursuant to which the Company agreed to file a registration statement by January&nbsp;20,
2021 with respect to the common stock underlying the Warrants. If at the time of exercise of the Warrants there is no effective
registration statement registering, or the prospectus contained therein is not available for the issuance of the common stock underlying
the Warrants to the applicable Selling Stockholder, then such Warrant may also be exercised, in whole or in part, at such time
by means of a &ldquo;cashless exercise&rdquo; in which the Selling Stockholder will be entitled to receive a number of shares of
common stock as determined by the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Private Placement is further described
in the Company&rsquo;s Periodic Report on Form&nbsp;8-K filed October&nbsp;14, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The private placement of the Warrants was
completed in reliance upon the exemption from registration provided for by Section&nbsp;4(a)(2)&nbsp;of the Securities Act and by Rule&nbsp;506 of Regulation D promulgated under the Securities Act. Each Selling
Stockholder represented to the Company in its Warrant Exercise Agreement that it is an &ldquo;accredited investor&rdquo; as that
term is defined in Rule&nbsp;501 of Regulation D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_011"></A>SELLING
STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have prepared this prospectus to allow
the Selling Stockholders we have identified herein, including their transferees, pledgees, donees and successors in interest, to
offer for resale up to 259,000 shares of our common stock (assuming exercise of all Warrants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The common stock being offered by the Selling
Stockholders is that issuable to the Selling Stockholders upon exercise of the Warrants. For additional information regarding the
issuances of those shares of common stock and Warrants, see &ldquo;Private Placement of Warrants&rdquo; above. We are registering
the shares of common stock in order to permit the Selling Stockholders to offer the Securities for resale from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The registration of the sale of shares of
common stock held by the Selling Stockholders does not mean that they will sell or otherwise dispose of all or any of those securities.
The Selling Stockholders may sell or otherwise dispose of all, a portion or none of such shares from time to time. See &ldquo;Plan
of Distribution.&rdquo; We do not know the number of shares, if any, that will be offered for sale or other disposition by any
of the Selling Stockholders under this prospectus. Furthermore, the Selling Stockholders may have sold, transferred or disposed
of the shares of common stock covered hereby in transactions exempt from the registration requirements of the Securities Act since
the date on which we filed this prospectus. As a result, we cannot estimate the number of shares of common stock each of the Selling
Stockholders will beneficially own after termination of sales under this prospectus. In addition, each of the Selling Stockholders
may have sold, transferred or otherwise disposed of all or a portion of its shares of common stock since the date on which it provided
information for the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with the terms of a registration
rights agreement with the Selling Stockholders, this prospectus generally covers the resale of the maximum number of shares of
common stock issuable upon exercise of the Warrants issued pursuant to the Warrant Exercise Agreements, determined as if the outstanding
Warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially
filed with the SEC, without regard to any limitations on the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as otherwise described in this prospectus,
none of the Selling Stockholders has, or within the past three years has had, any position, office or other material relationship
with us or any of our affiliates. None of the Selling Stockholders is a broker-dealer or an affiliate of a broker-dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below sets forth certain information
with respect to each Selling Stockholder, including (i)&nbsp;the name of each Selling Stockholder; (ii)&nbsp;the number of shares
of our common stock beneficially owned by each Selling Stockholder before this offering; (iii)&nbsp;the maximum number of shares
being offered by each Selling Stockholder pursuant to this prospectus; and (iv)&nbsp;each Selling Stockholder&rsquo;s beneficial
ownership after completion of this offering, assuming that all of the shares covered hereby (but no other shares, if any, held
by the Selling Stockholders) are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table is based on information supplied
to us by the Selling Stockholders or in Schedules 13G or 13D and other public documents filed with the SEC, with beneficial ownership
and percentage ownership determined in accordance with the rules&nbsp;and regulations of the SEC, and includes information with
respect to voting or investment power with respect to shares of stock. This information does not necessarily indicate beneficial
ownership for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The percentage of each Selling Stockholder&rsquo;s
ownership before and after this offering is based on 7,471,474 shares of common stock outstanding as of January&nbsp;15, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Name and Address of<BR> Selling Stockholders</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">No.&nbsp;of Shares of <BR> Common Stock<BR> Beneficially Owned <BR> Prior to this<BR> Offering</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage of <BR> Outstanding Shares<BR> of Common Stock<BR> Beneficially Owned <BR> Prior to this <BR> Offering<SUP>1</SUP></B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">No.&nbsp;of Shares of <BR> Common Stock<BR> Offered by Selling<BR> Stockholders</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.&nbsp;and Percentage<BR> of Outstanding<BR> Shares of Common <BR> Stock Beneficially <BR> Owned Subsequent<BR> to this Offering<SUP>2</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dillon Hill Capital, LLC<SUP>3</SUP></B></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">301,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">3.9</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif">201,000; 2.6%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dillon Hill Investment Company LLC<SUP>3</SUP></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">357,739</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">159,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">198,739; 2.6%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>Includes the common stock issued upon the exercise of the 2019 Warrants under the applicable Warrant Exercise Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP></FONT>We have assumed that the Selling Stockholders will not acquire beneficial ownership of any additional securities issued
by us during the Offering. Assumes all Warrants are exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT>
Based on a Schedule 13G/A filed with the SEC on January&nbsp;20, 2021, Bruce Grossman is the sole member of Dillon Hill Capital,
LLC and a trust of which Bruce Grossman&rsquo;s spouse is the co-trustee is the sole member of Dillon Hill Investment Company LLC.
As such, Bruce Grossman may be deemed to beneficially own the securities held of record by the Selling Stockholders. Bruce Grossman
disclaims any such beneficial ownership. The principal business address of Bruce Grossman is c/o Dillon Hill Capital LLC, 200 Business
Park Drive, Suite&nbsp;306, Armonk, NY 10504. If required, information about other selling stockholders, except for any future
transferees, pledgees, donees or successors of the Selling Stockholders named in the table above, will be set forth in a prospectus
supplement or amendment to the registration statement of which this prospectus is a part. Additionally, post-effective amendments
to the registration statement will be filed to disclose any material changes to the plan of distribution from the description contained
in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_012"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are registering the shares of common
stock issuable to the Selling Stockholders upon the exercise of the Selling Stockholders&rsquo; Warrants purchased in the Private
Placement to permit the resale of these shares of common stock by the holders of the shares of common stock from time to time after
the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholders of the shares of
common stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders, which may include
donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock
received after the date of this prospectus from a Selling Stockholder as a gift, pledge, partnership distribution or other transfer,
may sell all or a portion of the shares of common stock beneficially owned by them and offered hereby from time to time on any
stock exchange, market or trading facility on which the shares are traded or in private transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A Selling Stockholder may use any one or
more of the following methods when disposing of shares or interests therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of
the block as principal to facilitate the transaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its own account;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>an exchange distribution in accordance with the rules&nbsp;of the applicable exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>privately negotiated transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>through agreements between broker-dealers and the Selling Stockholders to sell a specified number of such shares at a stipulated
price per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>a combination of any such methods of sale; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>any other method permitted by applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders may, from time
to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in
the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from
time to time, under this prospectus, or under an amendment to this prospectus under Rule&nbsp;424(b)&nbsp;or other applicable provision
of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest
as selling stockholders under this prospectus. The Selling Stockholders also may transfer the shares of common stock in other circumstances,
in which case the pledgees, transferees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders also may resell
all or a portion of the shares in open market transactions in reliance upon Rule&nbsp;144 under the Securities Act, as permitted
by that rule, or Section&nbsp;4(a)(1)&nbsp;under the Securities Act, if available, rather than under this prospectus; provided
that they meet the criteria and conform to the requirements of those provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the sale of our common
stock or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The
Selling Stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions,
or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The Selling Stockholders may also
enter into options or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative
securities which require the delivery to each such broker-dealer or other financial institution of shares offered by this prospectus,
which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The aggregate proceeds to the Selling Stockholders
from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions,
if any. Each of the Selling Stockholders reserves the right to accept and, together with its agents from time to time, to reject,
in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the
proceeds from this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Selling Stockholders and any underwriters,
broker-dealers or agents that participate in the sale of the common stock or interests therein may be &ldquo;underwriters&rdquo;
within the meaning of Section&nbsp;2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on
any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling Stockholders who are &ldquo;underwriters&rdquo;
within the meaning of Section&nbsp;2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent required, the shares of our
common stock to be sold, the names of the Selling Stockholders, the respective purchase prices and public offering prices, the
names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will
be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If underwriters are used in the sale,
the shares of common stock will be acquired by the underwriters for their own account and may be resold from time to time in
one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined
at the time of sale. In connection with any such underwritten sale of shares of common stock, underwriters may receive
compensation from the Selling Stockholders, for whom they may act as agents, in the form of discounts, concessions or
commissions. If the Selling Stockholders use an underwriter or underwriters to effectuate the sale of shares of common stock,
we and/or they will execute an underwriting agreement with those underwriters at the time of sale of those shares of common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent required by law, the names
of the underwriters will be set forth in a prospectus supplement or, if appropriate, a post-effective amendment to the registration
statement that includes the prospectus supplement and the accompanying prospectus used by the underwriters to sell those securities.
The obligations of the underwriters to purchase those shares of common stock will be subject to certain conditions precedent, and
unless otherwise specified in a prospectus supplement, the underwriters will be obligated to purchase all the shares of common
stock offered by such prospectus supplement if any of such shares of common stock are purchased. Any public offering price and
any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have advised the Selling Stockholders
that the anti-manipulation rules&nbsp;of Regulation M under the Exchange Act may apply to sales of shares in the market and to
the activities of the Selling Stockholders and their affiliates. The Selling Stockholders may indemnify any broker-dealer that
participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are required to pay certain fees and
expenses incurred by us incident to the registration of the shares of common stock of the selling stockholders. We have agreed
to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the
Securities Act, and the Selling Stockholders may be entitled to contribution. We may be indemnified by the Selling Stockholders
against certain losses, claims, damages and liabilities, including liabilities under the Securities Act that may arise from any
written information furnished to us by the Selling Stockholders specifically for use in this prospectus, or we may be entitled
to contribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed with the Selling Stockholders
to keep the registration statement of which this prospectus forms a part effective until the earlier of (i)&nbsp;the date as of
which the Selling Stockholders may sell all of the common stock covered by such registration statement without restriction or limitation
pursuant to Rule&nbsp;144 and without the requirement to be in compliance with Rule&nbsp;144(c)(1)&nbsp;(or any successor thereto)
promulgated under the Securities Act or (ii)&nbsp;the date on which the Selling Stockholders shall have sold all of the common
stock covered by such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is listed on The Nasdaq
Capital Market under the symbol &ldquo;APDN.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_013"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The validity of the issuance of the Securities
offered hereby will be passed upon for us by Troutman Pepper Hamilton Sanders LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_014"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our <A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465920136828/tm2037742d1_10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form&nbsp;10-K for the year ended September&nbsp;30, 2020</A> (as amended)</FONT>, as set forth in their report, which includes
an explanatory paragraph as to the Company&rsquo;s ability to continue as a going concern as described in Note B to the consolidated
financial statements, dated December&nbsp;17, 2020, which is incorporated by reference in the prospectus and elsewhere in this
registration statement. Our consolidated financial statements are incorporated by reference in reliance on Marcum LLP&rsquo;s
report, given on their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_015"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have filed with the SEC a registration
statement on Form&nbsp;S-3 (File No.&nbsp;333-252280), of which this prospectus is a part, under the Securities Act, to register
the shares of common stock offered by this prospectus. However, this prospectus does not contain all of the information contained
in the Registration Statement. We have omitted from this prospectus some parts of the Registration Statement as permitted by the
rules&nbsp;and regulations of the SEC. Statements in this prospectus concerning any document we have filed as an exhibit to the
Registration Statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified in their
entirety by reference to these filings. In addition, we file annual, quarterly and other reports, proxy statements and other information
with the SEC. Our SEC filings are available to the public over the Internet at the SEC&rsquo;s website at www.sec.gov. Our Annual
Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, and Current Reports on Form&nbsp;8-K, including any amendments to
those reports, and other information that we file with or furnish to the SEC pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of
the Exchange Act can also be accessed free of charge through the Internet. These filings will be available as soon as reasonably
practicable after we electronically file such material with, or furnish it to, the SEC. Annual Reports on Form&nbsp;10-K, Quarterly
Reports on Form&nbsp;10-Q and Current Reports on Form&nbsp;8-K, including any amendments to those reports, and other information
that we file with or furnish to the SEC pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act, can also be accessed
free of charge from our website at http://www.adnas.com. These filings will be available as soon as reasonably practicable after
we electronically file such material with, or furnish it to, the SEC. Information contained on our website is not part of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ss_016"></A>INFORMATION
INCORPORATED BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have elected to incorporate certain information
by reference into this prospectus. By incorporating by reference, we can disclose important information to you by referring you
to other documents we have filed or will file with the SEC. The information incorporated by reference is deemed to be part of this
prospectus, except for information incorporated by reference that is superseded by information contained in this prospectus. This
means that you must look at all of the SEC filings that we incorporate by reference to determine if any statements in the prospectus
or any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference
the documents set forth below that we have previously filed with the SEC, except in each case the information contained in such
document to the extent &ldquo;furnished&rdquo; and not &ldquo;filed&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465920136828/tm2037742d1_10k.htm" STYLE="-sec-extract: exhibit">Our Annual Report on Form&nbsp;10-K for the year ended September&nbsp;30, 2020, as filed with the SEC on December&nbsp;17, 2020</A>, as amended by <A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921008158/tm214175d1_10ka.htm" STYLE="-sec-extract: exhibit">Amendment No.&nbsp;1 filed on January&nbsp;27, 2021</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465920113418/tm2032734d1_8k.htm" STYLE="-sec-extract: exhibit">Our Current Report on Form&nbsp;8-K, as filed with the SEC on October&nbsp;8, 2020</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465920114880/tm2033064d1_8k.htm" STYLE="-sec-extract: exhibit">Our Current Report on Form&nbsp;8-K, as filed with the SEC on October&nbsp;14, 2020</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465920116419/tm2033883-1_8k.htm" STYLE="-sec-extract: exhibit">Our Current Report on Form&nbsp;8-K, as filed with the SEC on October&nbsp;20, 2020</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921002738/tm212720d1_8k.htm" STYLE="-sec-extract: exhibit">Our Current Report on Form&nbsp;8-K, as filed with the SEC on January&nbsp;11, 2021</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921003781/tm212922-2_8k.htm" STYLE="-sec-extract: exhibit">Our Current Report on Form&nbsp;8-K, as filed with the SEC on January&nbsp;13, 2021</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465921005882/tm213709d1_8k.htm" STYLE="-sec-extract: exhibit">Our Current Report on Form&nbsp;8-K, as filed with the SEC on January&nbsp;20, 2021</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000157104914006275/t1402186_8a12b.htm" STYLE="-sec-extract: exhibit">The description of our capital stock contained in our registration statement on Form&nbsp;8-A (File No.&nbsp;001-36745) filed with the Commission on November&nbsp;13, 2014, pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act, including any amendment or report filed for the purpose of updating such description</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All reports and other documents subsequently
filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d)&nbsp;of the Exchange Act after the date of the registration statement
to which this prospectus forms a part of and prior to the effectiveness of such registration statement or after the date of this
prospectus and prior to the termination or completion of the offering of Securities under this prospectus shall be deemed to be
incorporated by reference in this prospectus and to be a part hereof from the date of filing such reports and other documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may obtain a copy of any or all of the
documents referred to above which may have been or may be incorporated by reference into this prospectus, except for exhibits to
those documents (unless the exhibits are specifically incorporated by reference into those documents) at no cost to you by writing
or telephoning us at the following address: Office of the Corporate Secretary, Applied DNA Sciences,&nbsp;Inc., 50 Health Sciences
Drive, Stony Brook, New York 11790, telephone (631) 240-8800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Annual Reports on Form&nbsp;10-K, Quarterly
Reports on Form&nbsp;10-Q and Current Reports on Form&nbsp;8-K, including any amendments to those reports, and other information
that we file with or furnish to the SEC pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act, can also be accessed
free of charge from our website at http://www.adnas.com. These filings will be available as soon as reasonably practicable after
we electronically file such material with, or furnish it to, the SEC. Information contained on our website is not part of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; padding: 0.5pt 1.25pt"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U><IMG SRC="tm215233d1_424b3img001.jpg" ALT="" STYLE="height: 55px; width: 343px"></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>259,000 Shares</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offered by the Selling Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>February&nbsp;3, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 1%; padding: 1pt"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 98%; padding: 1pt"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; padding: 1pt"><FONT STYLE="font-size: 0pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; padding: 0.5pt 1.25pt"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm215233d1_424b3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm215233d1_424b3img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  W 5<# 2(  A$! Q$!_\0
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MCE!D<OC]XX<$GR\  _5C]C+]O#X5_M^_"<>,_A5XNLO%.C))Y%R(T>&ZT^7
M;RIX7"R1M@Y&Y<$<J2.:\#_;@_X.#?V9/V!_BA-X+\7^,;[5?%=DP6_TSP_I
MSZA)I9(SMG<%8T?_ &-^\=U%?G=_P3F/AK]E;_@X0_:O\/\ P#>#_A4ND> K
M_4KJRL)O-TVTO8(K*4HAR5Q#>R7,2#^ -(B\ UL_\&FOP"^"W[2_P*^*GCGQ
MUHWA?XA_&>_\57 UE_$-I#J5W;V,L,4B2K',K;5FF>Y+R#ERFTGY<4 ?K/\
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B\VTX!*APN>U%% 'T((PO:G444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
